Xcout IntelImmunome, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Immunome, Inc. among biotechnology companies — ranked by similarity to what Immunome, Inc. actually does, not by market-cap band.
Subscribe to see Immunome, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Immunome, Inc.
Immunome Inc. is a public, clinical-stage targeted oncology company committed to reinventing antibody-drug conjugates, with its headquarters located in Bothell, Washington.
Immunome, Inc. at a glance
Immunome, Inc. is a biotechnology company headquartered in Bothell, United States. It is publicly listed (IMNM) with a market capitalisation of $1.9B. Xcout tracks 15 named people at Immunome, Inc., including Clay Siegall (Chairman, President & Chief Executive Officer). Xcout recorded 56 job postings from Immunome, Inc. in the last 90 days.
Immunome, Inc. leadership
- Clay SiegallChairman, President & Chief Executive Officer
- Max RosettChief Financial Officer
- Philip TsaiChief Technical Officer
- Jack HigginsChief Scientific Officer
- Robert J. LechleiderChief Medical Officer
- Sandra G. StonemanChief Legal Officer, General Counsel & Corporate Secretary
9 more named people on record for Immunome, Inc., with roles, board committees and tenure — see the full roster →
Hiring at Immunome, Inc.
Xcout recorded 56 job postings from Immunome, Inc. in the last 90 days, from a hiring record Xcout has kept since June 2026.
The weekly hiring trend, the roles and locations behind it — see Immunome, Inc.'s hiring signals →
Top 12 Immunome, Inc. competitors
Ranked by semantic similarity — how close each company is to Immunome, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
Immune Design Corp. is a clinical-stage immunotherapy company with offices in Seattle, Washington, and South San Francisco, California, specializing in novel drug discovery and treatment technologies.
Similar biotechnology company
Centrose LLC is a biotechnology company that develops a next-generation antibody-drug conjugate platform known as Extracellular Drug Conjugates (EDCs). These precision medicines target the cell surfaceome by binding multiple extracellular proteins simultaneously without cell internalization or drug release, aiming to create safer and more potent treatments for cancer and drug-resistant tumors.
Similar biotechnology company
BridGene Biosciences, Inc. is a biotechnology company headquartered in San Jose, California, pioneering next-generation chemoproteomics through its IMTAC platform. The company is focused on discovering and developing innovative small molecule drugs for high-value targets.
Similar biotechnology company
LigaChem Biosciences is a clinical-stage biopharmaceutical company headquartered in Daejeon, South Korea. The company specializes in the discovery and development of novel therapeutics utilizing proprietary technology platforms such as antibody-drug conjugates. With decades of dedicated drug development experience, it drives global healthcare innovation through open collaboration.
Similar biotechnology company
BIND Therapeutics, Inc. is a clinical-stage nanomedicine company headquartered in Cambridge, Massachusetts. The company specializes in developing targeted and programmable therapeutics using its proprietary platform to treat various diseases.
Similar biotechnology company
Defence Therapeutics is a publicly traded Canadian biotechnology company headquartered in Montreal, Quebec. It is a precision intracellular drug-delivery company focused on unlocking the full potential of cancer biologics.
Similar biotechnology company
Normunity Holding Company, LLC is a biotechnology company developing novel anti-cancer therapies and biologic medicines, including therapeutic antibodies, bispecific antibodies, and T cell engagers. The company utilizes proprietary discovery platforms originating from a partnership with the Yale School of Medicine to target mechanisms at the interface of tumors and the immune system.
Life Sciences
ImStar Therapeutics Inc. is a biotechnology company headquartered in Vancouver, British Columbia, focused on breakthrough science and drug discovery.
Biotech
Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of innovative therapeutic products. Its primary objective is to create protein-based treatments for challenging conditions like cancer and autoimmune disorders. The company achieves this through its proprietary XpressCF+ platform, a unique technology that integrates cell-free protein synthesis with precise, site-specific drug conjugation. Currently, Sutro's pipeline features two lead antibody-drug conjugate (ADC) candidates, both undergoing Phase 1 clinical evaluation. STRO-001 targets the CD74 protein, designed for individuals with multiple myeloma and non-Hodgkin lymphoma. The second candidate, STRO-002, is engineered to bind to folate receptor-alpha, intended for the treatment of ovarian and endometrial cancers. Strategic alliances are also a key part of its strategy, including collaborations and licensing agreements. A partnership with Merck aims to advance research programs involving cytokine derivatives for both oncological and autoimmune applications. Additionally, an agreement with Celgene Corporation focuses on identifying and developing bispecific antibodies and/or ADCs specifically within the immuno-oncology domain. Founded in 2003, the company initially operated under the name Fundamental Applied Biology, Inc. Its corporate headquarters are located in South San Francisco, California.
Similar biotechnology company
Avammune Therapeutics is an R&D-driven drug discovery company headquartered in Philadelphia, Pennsylvania. The company focuses on developing novel, modality-agnostic immunotherapies and cancer therapies to address high unmet medical needs in hard-to-treat solid tumors.
Biotech
IntoCell is a South Korean biotechnology company founded in 2015 and headquartered in Daejeon, specializing in drug-conjugate and related pharmaceutical technologies.
Biotech
Chiome Bioscience Inc. engages in the research and development of drug discovery technology platforms worldwide. It operates in two segments, Drug Discovery Business and Drug Discovery Support Business. The company offers ADLib System, a technology for generating monoclonal antibodies which is used to generate antibodies for drug discovery research; and Human ADLib System, which converts chicken antibody genes to humanized antibodies. It also provides protein expression and purification services; stable cell line development services for recombinant protein and antibody production; and antibody generation services using the ADLib system. In addition, the company's product pipeline under Phase 1 trial comprises ADCT-701, an anti-dlk1 antibody for treating liver cancer; CBA-1205, an afucosylated anti-dlk1 antibody for liver cancer, lung cancer, and neuroblastoma; and CBA-1535, an anti 5T4/WAIF1 antibody for malignant mesothelioma, small cell lung cancer, non-small cell lung cancer, and triple negative breast cancer (TNBC). Further, its product pipeline under preclinical study includes PCDC, an anti- CDCP1 antibody for lung, colorectal, pancreatic, breast, and ovarian tumors; PTRY, an antibody 5T4/CD3/PD-L1 for treating malignant mesothelioma, small cell lung cancer, non-small cell lung cancer, and TNBC; BMAA, an anti-semphorin3a antibody for treating renal and other diseases; LIV-2008/2008b, an anti-TROP-2 antibody for the treatment of TNBC, lung cancer, and colorectal cancer; PFKR, an anti-CX3CR1 antibody for secondary progressive multiple sclerosis; and PXLR, an anti-CXCL1/2/3/5 antibody for the treatment of gastric, breast, and ovarian tumors. Chiome Bioscience Inc. was incorporated in 2005 and is headquartered in Tokyo, Japan.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Immunome, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Immunome, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →